Capricor provides HOPE-3 trial update via slide presentation, no new data disclosed

CAPRICOR THERAPEUTICS, INC.

Filed Item 7.01 with slide presentation dated Dec 3, 2025 on HOPE-3 Phase 3 top-line results.
Slide presentation contains no specific efficacy or safety numbers in the attached exhibit.
Company held conference call; full slides available on investor website.
No materially new financial or clinical information beyond prior top-line announcement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.